Cancer Cell Biology

You have full text access to this OnlineOpen article

Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity

  1. James P. Moran,
  2. Scott A. Gerber,
  3. Celeste A. Martin,
  4. John G. Frelinger,
  5. Edith M. Lord†,*

Article first published online: 18 JUN 2003

DOI: 10.1002/ijc.11284

Issue

International Journal of Cancer

International Journal of Cancer

Volume 106, Issue 5, pages 690–698, 20 September 2003

Additional Information

How to Cite

Moran, J. P., Gerber, S. A., Martin, C. A., Frelinger, J. G. and Lord, E. M. (2003), Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int. J. Cancer, 106: 690–698. doi: 10.1002/ijc.11284

Author Information

  1. Department of Microbiology and Immunology and James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA

  1. †

    Fax: +585-461-4019

*Cancer Center, University of Rochester, Box 704, 601 Elmwood Ave. Rochester, NY, USA

Publication History

  1. Issue published online: 10 JUL 2003
  2. Article first published online: 18 JUN 2003
  3. Manuscript Accepted: 11 APR 2003
  4. Manuscript Revised: 28 MAR 2003
  5. Manuscript Received: 16 SEP 2002

Funded by

  • NIH. Grant Numbers: CA28332, AI007285
  • Ronald E. McNair Program

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (347K)

REFERENCES

  • 1
    Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83–243.
  • 2
    Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 1999; 19: 114–20.
  • 3
    Shah AU, D'Souza MJ. Sustained-release interleukin-12 microspheres in the treatment of cancer. Drug Dev Ind Pharm 1999; 25: 995–1004.
  • 4
    Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001; 22: 113–5.
  • 5
    Golab J, Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies(Review). Int J Mol Med 1999; 3: 537–44.
  • 6
    Uno K, Setoguchi J, Tanigawa M, Kishi A, Ogawa M, Saotome H, Fujiwara H, Kishida T. Differential interleukin 12 responsiveness for interferon gamma production in advanced stages of cancer patients correlates with performance status. Clin Cancer Res 1998; 4: 2425–32.
  • 7
    Hoshino T, Jiang YZ, Dunn D, Paul D, Qazilbash M, Cowan K, Wang J, Barrett J, Liu J. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. Cancer Gene Ther 1998; 5: 150–7.
  • 8
    Kurzawa H, Wysocka M, Aruga E, Chang AE, Trinchieri G, Lee WM. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 1998; 58: 491–9.
  • 9
    Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH Jr, Moore JS, Koblish HK, Lee J, Lord EM, Trinchieri G, Lee WM. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 1999; 59: 4882–9.
  • 10
    Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotz MT. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697–706.
  • 11
    Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW, Street NE. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1999; 162: 2842–9.
  • 12
    Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749–95.
  • 13
    Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581–6.
  • 14
    Coughlin CM, Wysocka M, Trinchieri G, Lee WM. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res 1997; 57: 2460–7.
  • 15
    Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877–82.
  • 16
    Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927–32.
  • 17
    Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–8.
  • 18
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–64.
  • 19
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6.
  • 20
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
  • 21
    Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, Klein TW, Hua Y. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399–403.
  • 22
    Rhodes LD, Paull AT, Sibley CH. Two different IFN-gamma nonresponsive variants derived from the B-cell lymphoma 70Z/3. Immunogenetics 1994; 40: 199–209.
  • 23
    Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA 1987; 84: 4831–5.
  • 24
    Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 1972; 49: 735–749.
  • 25
    Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979; 63: 541–8.
  • 26
    Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112–7.
    Direct Link:
  • 27
    Sonouchi K, Hamilton TA, Tannenbaum CS, Tubbs RR, Bukowski R, Finke JH. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. Am J Pathol 1994; 144: 747–55.
  • 28
    Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 1993; 53: 2112–7.
  • 29
    Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med 1993; 178: 1103–7.
  • 30
    Tanaka T, Tsudo M, Karasuyama H, Kitamura F, Kono T, Hatakeyama M, Taniguchi T, Miyasaka M. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol 1991; 147: 2222–8
  • 31
    Woods ML, McAdam AJ, Frelinger JG, Lord EM. Isolation and expansion of tumor-infiltrating lymphocytes. Biotechniques 1993; 15: 970–2.
  • 32
    Maryanski JL, Van Snick J, Cerottini JC, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 1982; 12: 401–6.
    Direct Link:
  • 33
    Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993; 53: 5721–6.
  • 34
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
  • 35
    Gerber SA, Moran JP, Frelinger JG, Fenton BM, Lord EM. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer 2003; 88: 1453–61.
  • 36
    Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795–800.
  • 37
    Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995; 92: 768–72.
  • 38
    Waleh NS, Brody MD, Knapp MA, Mendonca HL, Lord EM, Koch CJ, Laderoute KR, Sutherland RM. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res 1995; 55: 6222–6.
  • 39
    Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671–4.
  • 40
    Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–8.
  • 41
    Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 1998; 58: 1478–85.
  • 42
    Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963–9.
  • 43
    Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195–204.
  • 44
    Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361–5.
    Direct Link:
  • 45
    Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149–53.
  • 46
    Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9: 25–34.
  • 47
    Lee JC, Kim DC, Gee MS, Saunders HM, Sehgal CM, Feldman MD, Ross SR, Lee WM. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 2002; 62: 747–55
  • 48
    Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells. Science 1993; 259: 368–70.
  • 49
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995; 55: 4980–7.
  • 50
    Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz de Cerio A, Qian C, Xie X, Borras-Cuesta F, Prieto J. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 1999; 162: 5270–7.
  • 51
    Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J Exp Med 1998; 188: 1603–10.
  • 52
    Gherardi MM, Ramirez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000; 74: 6278–86.
  • 53
    Peter K, Brunda MJ, Corradin G. IL-12 administration leads to a transient depletion of T cells, B cells, and APCs and concomitant abrogation of the HLA-A2.1-restricted CTL response in transgenic mice. J Immunol 2002; 169: 63–7.
  • 54
    Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 2001; 130: 470–8.
  • 55
    Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT. Murine models of cancer cytokine gene therapy using interleukin-12. Ann NY Acad Sci 1996; 795: 275–83.
    Direct Link:
  • 56
    Hegde SP, Bright JJ, Kausalya S, Khar A. AK-5 tumor-induced expression of interleukin-12: role of IL-12 in NK-mediated AK-5 regression. Cell Immunol 1995; 162: 241–7.
  • 57
    Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR, Wiltrout RH. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 1998; 161: 6014–21.
  • 58
    Kito T, Kuroda E, Yokota A, Yamashita U. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide. J Neurosurg 2003; 98: 385–92.
  • 59
    Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001; 166: 3890–9.
  • 60
    Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB. Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother 2001; 24: 37–45.
  • 61
    Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther 2000; 11: 1269–75.
  • 62
    O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997; 15: 5–13.
  • 63
    Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20: 79–86.
View Full Article (HTML) Get PDF (347K)